
Jamie P. Dwyer MD
Acute Renal Failure, Chronic Renal Failure & Dialysis, Glomerular Disease, Hypertension
Executive Associate Vice President of Research; Professor of Medicine, Division of Nephrology &Hypertension; Director, Clinical Research Support Office in the Clinical and Translational Science Institute; and Director, Utah Data Coordinating Center in the Spencer Fox Eccles School of Medicine at the University of Utah; and Principal Investigator of the Collaborative Study Group
Office of the Dean6311 Garners Ferry RdColumbia, SC 29209
Dr. Dwyer is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a physician-scientist, health-system leader, clinical trialist, and academic innovator working at the intersection of medicine, research, education, and healthcare delivery.
I am Dean of the Kay and C. Edward Floyd, M.D. School of Medicine at the University of South Carolina, where I am focused on advancing the school's missions in education, research, clinical care, and service while strengthening its partnership with health systems. The future of academic medicine depends on bringing these missions together rather than treating them as separate enterprises.
Previously, I served as Executive Associate Vice President for Research and Chief Innovation Officer at the University of Utah, where I led university-wide innovation strategy, commercialization, entrepreneurship and venture creation, and industry partnerships. I also led the Utah Data Coordinating Center, a large academic research organization supporting complex, multisite clinical research.
My academic work centers on nephrology, hypertension, and cardiorenal-metabolic disease, particularly the design, conduct, and analysis of large-scale RCTs. I have led and advised multinational trials, served on FDA advisory committees, evaluated renal safety signals in clinical development programs, and worked extensively in protocol design, endpoint development, and medical monitoring. I remain a practicing nephrologist and have co-founded healthcare companies, including Innovative Renal Care and Corventum.
I am interested in the future of academic medicine: educating physicians differently, building research enterprises that operate at scale via coordination science, using data and AI responsibly, accelerating therapeutic development, and creating health systems that continuously learn and improve.
Education & Training
Vanderbilt University Medical CenterFellowship, Nephrology, 2004 - 2006
Mayo Clinic College of Medicine and Science (Jacksonville)Chief Residency, Internal Medicine, 2003 - 2004
Mayo Clinic College of Medicine and Science (Jacksonville)Residency, Internal Medicine, 2000 - 2003
The Warren Alpert Medical School of Brown UniversityClass of 2000
Brown UniversityScB, Mathematics and Classics:Latin, 1992 - 1996
Certifications & Licensure
UT State Medical License 2021 - 2028
TN State Medical License 2008 - 2023
AL State Medical License 2020 - 2020
FL State Medical License 2001 - 2009
KY State Medical License 2005 - 2007
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Nephrology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification BI-Clinical, CitiusTech, Inc., 2013, 2015-2017
- CMS Meaningful Use Stage 2 Certification StarPanel, Vanderbilt University, 2013, 2015-2017
- CMS Meaningful Use Stage 1 Certification StarPanel, Vanderbilt University, 2013, 2015-2017
Clinical Trials
Publications & Presentations
PubMed
- Combined Aldosterone Synthase and SGLT2 Inhibition: A Recipe for Success in CKD with Uncontrolled Blood Pressure?Jacob M Dunn, Stephen R Sammons, Kausik Umanath, Jamie P Dwyer
Current Hypertension Reports. 2026-06-12 - A double-blind, randomized, placebo-controlled, phase 2 trial examined the efficacy and safety of monlunabant in adults with diabetic kidney disease.David Z I Cherney, Karen Bonefeld, Glenn Crater, Jamie P Dwyer, Ofir Frenkel
Kidney International. 2026-06-01 - Midazolam Dosing During CRRT: A Combined Ex Vivo and Physiologically-Based Pharmacokinetic Approach.Autumn M McKnite, Abdullah Hamadeh, J Porter Hunt, Danielle J Green, Carina Imburgia
CPT. 2026-05-01
Press Mentions
AHA Recognizes Dr. Jamie Dwyer for Hypertension StudyOctober 22nd, 2025
New Pill Lowers Stubborn Blood Pressure and May Slow Kidney DiseaseOctober 4th, 2025
New Medication Lowered Hard-to-Control High Blood Pressure in People with Chronic Kidney DiseaseSeptember 6th, 2025
Grant Support
- HEAL ERN: Data Coordinating Resource CenterUNIVERSITY OF UTAH2022–2027
External Links
- LinkedInhttps://www.linkedin.com/in/jamiepdwyer/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









